Adma Biologics (ADMA) Ascends While Market Falls: Some Facts to Note

Adma Biologics (ADMA) closed the most recent trading day at $16.32, moving +2.06% from the previous trading session.

Zacks Investment Research • Feb 19, 2026

ADMA Biologics to Report Fourth Quarter and Full Year 2025 Financial Results on February 25, 2026

RAMSEY, N.J. and BOCA RATON, Fla.

GlobeNewsWire • Feb 18, 2026

Adma Biologics (ADMA) Registers a Bigger Fall Than the Market: Important Facts to Note

Adma Biologics (ADMA) closed at $15.59 in the latest trading session, marking a -4.24% move from the prior day.

Zacks Investment Research • Feb 12, 2026

Adma Biologics (ADMA) Exceeds Market Returns: Some Facts to Consider

In the closing of the recent trading day, Adma Biologics (ADMA) stood at $17.5, denoting a +1.16% move from the preceding trading day.

Zacks Investment Research • Feb 2, 2026

Is It Worth Investing in Adma Biologics (ADMA) Based on Wall Street's Bullish Views?

When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts often influence a stock's price, but are they really important?

Zacks Investment Research • Jan 29, 2026

ADMA Gains 13.8% in Three Months: More Upside Potential for 2026?

ADMA shares rose 13.8% over three months as demand for Asceniv surged, driving higher 2026 revenues and EBITDA targets amid margin expansion.

Zacks Investment Research • Jan 22, 2026

Adma Biologics (ADMA) Increases Despite Market Slip: Here's What You Need to Know

Adma Biologics (ADMA) concluded the recent trading session at $17.59, signifying a +1.62% move from its prior day's close.

Zacks Investment Research • Jan 21, 2026

ADMA Biologics: Business Update And My Price Target

ADMA Biologics was trading poorly in early 2021, near $2 per share. My thesis centered on ADMA's asset value, including plasma centers, matching its enterprise value. Strong revenue growth, insider buying, and a poison pill signaled management's confidence in profitability.

Seeking Alpha • Jan 14, 2026

ADMA Biologics Reports Preliminary 2025 Results, Ups 2026 Outlook

ADMA expects 2025 revenues of approximately $510-$511 million, raising 2026 guidance on strong Asceniv demand and margin expansion.

Zacks Investment Research • Jan 13, 2026

Is Adma Biologics (ADMA) a Buy as Wall Street Analysts Look Optimistic?

When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts often influence a stock's price, but are they really important?

Zacks Investment Research • Jan 13, 2026